SBC Medical Group (NASDAQ:SBC) Issues Quarterly Earnings Results

SBC Medical Group (NASDAQ:SBC) posted its quarterly earnings data on Thursday. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01, FiscalAI reports. The business had revenue of $43.06 million during the quarter, compared to analyst estimates of $41.66 million. SBC Medical Group had a net margin of 29.37% and a return on equity of 20.76%.

Here are the key takeaways from SBC Medical Group’s conference call:

• Q1 2026 revenue was $43 million, down 9% year over year, but management said the decline was mainly due to prior fee-structure revisions and a one-time gain in the prior-year quarter.
• Excluding the fee-structure impact and AHH consolidation timing, management said underlying revenue grew 111% YoY and underlying EBITDA grew 117% YoY, highlighting strong core growth.
• Management said clinic traffic, repeat visits, and average spend per visit improved, and that competitive pressure in the Japanese and global aesthetics market has eased somewhat.
• The company expects margins to remain stable and improve over time, supported by AI initiatives aimed at boosting customer experience and lowering labor and operating costs.
• On capital allocation, SBC Medical said growth investment and disciplined M&A remain the priority, while share buybacks are not a high priority right now and the company is focused instead on improving liquidity and float.

SBC Medical Group Trading Down 0.3%

SBC Medical Group stock traded down $0.01 during trading on Friday, reaching $2.97. The company had a trading volume of 122,552 shares, compared to its average volume of 70,183. SBC Medical Group has a 12-month low of $2.95 and a 12-month high of $5.75. The stock’s 50 day moving average price is $3.77 and its two-hundred day moving average price is $3.94. The firm has a market capitalization of $304.66 million, a price-to-earnings ratio of 6.06 and a beta of 0.61. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.74 and a current ratio of 3.78.

Insider Transactions at SBC Medical Group

In related news, CEO Yoshiyuki Aikawa sold 465,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $3.02, for a total value of $1,404,300.00. Following the completion of the sale, the chief executive officer directly owned 78,839,460 shares in the company, valued at approximately $238,095,169.20. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 7,987,900 shares of company stock valued at $20,142,848 in the last ninety days. 89.47% of the stock is currently owned by insiders.

Institutional Investors Weigh In On SBC Medical Group

Institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in SBC Medical Group in the fourth quarter valued at approximately $49,000. Russell Investments Group Ltd. grew its holdings in SBC Medical Group by 292.0% in the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock valued at $51,000 after purchasing an additional 8,771 shares during the period. Nuveen LLC purchased a new stake in SBC Medical Group during the fourth quarter worth approximately $53,000. Wells Fargo & Company MN grew its stake in SBC Medical Group by 195.1% during the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock worth $54,000 after buying an additional 8,348 shares during the period. Finally, XTX Topco Ltd purchased a new stake in SBC Medical Group during the second quarter worth approximately $64,000. 60.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Weiss Ratings raised shares of SBC Medical Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Wall Street Zen raised shares of SBC Medical Group to a “hold” rating in a research report on Saturday, May 9th. Finally, BTIG Research assumed coverage on shares of SBC Medical Group in a research report on Friday, March 6th. They issued a “buy” rating and a $8.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

About SBC Medical Group

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.